OVEREXPRESSION FGFR2B

Clinical trials for OVEREXPRESSION FGFR2B explained in plain language.

Never miss a new study

Get alerted when new OVEREXPRESSION FGFR2B trials appear

Sign up with your email to follow new studies for OVEREXPRESSION FGFR2B, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet finished but already full! 1

Targeted attack on stomach cancer halted before it began

Disease control Terminated

This study aimed to see if adding a new targeted drug, bemarituzumab, to standard chemotherapy could better treat certain stomach and gastroesophageal junction cancers before and after surgery. It was designed for patients whose cancer cells had high levels of a specific protein …

Matched conditions: OVEREXPRESSION FGFR2B

Phase: PHASE2 • Sponsor: Institut Cancerologie de l'Ouest • Aim: Disease control

Last updated Mar 20, 2026 14:48 UTC

OVEREXPRESSION FGFR2B

Get alerted when new OVEREXPRESSION FGFR2B trials appear

Targeted attack on stomach cancer halted before it began